Literature DB >> 26254454

Outcomes of lower extremity revascularization among the hemodialysis-dependent.

John M Fallon1, Philip P Goodney2, David H Stone2, Virendra I Patel3, Brian W Nolan2, Jeffrey A Kalish4, Yuanyuan Zhao2, Allen D Hamdan5.   

Abstract

OBJECTIVE: Optimal patient selection for lower extremity revascularization remains a clinical challenge among the hemodialysis-dependent (HD). The purpose of this study was to examine contemporary real world open and endovascular outcomes of HD patients to better facilitate patient selection for intervention.
METHODS: A regional multicenter registry was queried between 2003 and 2013 for HD patients (N = 689) undergoing open surgical bypass (n = 295) or endovascular intervention (n = 394) for lower extremity revascularization. Patient demographics and comorbidities were recorded. The primary outcome was overall survival. Secondary outcomes included graft patency, freedom from major adverse limb events, and amputation-free survival (AFS). Multivariate analysis was performed to identify independent risk factors for death and amputation.
RESULTS: Among the 689 HD patients undergoing lower extremity revascularization, 66% were male, and 83% were white. Ninety percent of revascularizations were performed for critical limb ischemia and 8% for claudication. Overall survival at 1, 2, and 5 years survival remained low at 60%, 43%, and 21%, respectively. Overall 1- and 2-year AFS was 40% and 17%. Mortality accounted for the primary mode of failure for both open bypass (78%) and endovascular interventions (80%) at two years. Survival, AFS, and freedom from major adverse limb event outcomes did not differ significantly between revascularization techniques. At 2 years, endovascular patency was higher than open bypass (76% vs 26%; 95% confidence interval [CI], 0.28-0.71; P = .02). Multivariate analysis identified age ≥80 years (hazard ratio [HR], 1.9; 95% CI, 1.4-2.5; P < .01), indication of rest pain or tissue loss (HR, 1.8; 95% CI, 1.3-2.6; P < .01), preoperative wheelchair/bedridden status (HR, 1.5; 95% CI, 1.1-2.1; P < .01), coronary artery disease (HR, 1.5; 95% CI, 1.2-1.9; P < .01), and chronic obstructive pulmonary disease (HR, 1.4; 95% CI, 1.1-1.8; P = .01) as independent predictors of death. The presence of three or more risk factors resulted in predicted 1-year mortality of 64%.
CONCLUSIONS: Overall survival and AFS among HD patients remains poor, irrespective of revascularization strategy. Mortality remains the primary driver for these findings and justifies a prudent approach to patient selection. Focus for improved results should emphasize predictors of survival to better identify those most likely to benefit from revascularization.
Copyright © 2015 Society for Vascular Surgery. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26254454      PMCID: PMC5315419          DOI: 10.1016/j.jvs.2015.06.203

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  30 in total

1.  Outcome of infrainguinal bypass surgery for critical leg ischaemia in patients with chronic renal failure.

Authors:  S Peltonen; F Biancari; L Lindgren; H Mäkisalo; E Honkanen; M Lepäntalo
Journal:  Eur J Vasc Endovasc Surg       Date:  1998-02       Impact factor: 7.069

2.  Peripheral arterial disease in patients with end-stage renal disease: observations from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Sanjay Rajagopalan; Santo Dellegrottaglie; Anna L Furniss; Brenda W Gillespie; Sudtida Satayathum; Norbert Lameire; Akira Saito; Takashi Akiba; Michel Jadoul; Nancy Ginsberg; Marcia Keen; Friedrich K Port; Debabrata Mukherjee; Rajiv Saran
Journal:  Circulation       Date:  2006-10-23       Impact factor: 29.690

3.  Long-term outcomes and predictors of iliac angioplasty with selective stenting.

Authors:  Toshifumi Kudo; Fiona A Chandra; Samuel S Ahn
Journal:  J Vasc Surg       Date:  2005-09       Impact factor: 4.268

4.  Predictors of failure and success of tibial interventions for critical limb ischemia.

Authors:  Nathan Fernandez; Ryan McEnaney; Luke K Marone; Robert Y Rhee; Steven Leers; Michel Makaroun; Rabih A Chaer
Journal:  J Vasc Surg       Date:  2010-10       Impact factor: 4.268

5.  A decade experience with infrainguinal revascularization in a dialysis-dependent patient population.

Authors:  Pranay Ramdev; Sunil S Rayan; Malachi Sheahan; Allen D Hamdan; Frank W Logerfo; Cameron M Akbari; David R Campbell; Frank B Pomposelli
Journal:  J Vasc Surg       Date:  2002-11       Impact factor: 4.268

6.  Infrainguinal bypass grafting in patients with end-stage renal disease: improving outcomes?

Authors:  J C Lantis; M S Conte; M Belkin; A D Whittemore; J A Mannick; M C Donaldson
Journal:  J Vasc Surg       Date:  2001-06       Impact factor: 4.268

7.  Infrainguinal bypass in patients with end-stage renal disease.

Authors:  H R Baele; J J Piotrowski; J Yuhas; C Anderson; J J Alexander
Journal:  Surgery       Date:  1995-03       Impact factor: 3.982

8.  Endovascular treatment for infrainguinal vessels in patients with critical limb ischemia: OLIVE registry, a prospective, multicenter study in Japan with 12-month follow-up.

Authors:  Osamu Iida; Masato Nakamura; Yasutaka Yamauchi; Daizo Kawasaki; Yoshiaki Yokoi; Hiroyoshi Yokoi; Yoshimistu Soga; Kan Zen; Keisuke Hirano; Nobuhiro Suematsu; Naoto Inoue; Kenji Suzuki; Yoshiaki Shintani; Yusuke Miyashita; Kazushi Urasawa; Ikuro Kitano; Terutoshi Yamaoka; Takashi Murakami; Michitaka Uesugi; Taketsugu Tsuchiya; Toshiro Shinke; Yasuhiro Oba; Norihiko Ohura; Toshimitsu Hamasaki; Shinsuke Nanto
Journal:  Circ Cardiovasc Interv       Date:  2013-01-29       Impact factor: 6.546

9.  Failure of foot salvage in patients with end-stage renal disease after surgical revascularization.

Authors:  B L Johnson; M H Glickman; D F Bandyk; G E Esses
Journal:  J Vasc Surg       Date:  1995-09       Impact factor: 4.268

10.  Factors associated with amputation or graft occlusion one year after lower extremity bypass in northern New England.

Authors:  Philip P Goodney; Brian W Nolan; Andres Schanzer; Jens Eldrup-Jorgensen; Daniel J Bertges; Andrew C Stanley; David H Stone; Daniel B Walsh; Richard J Powell; Donald S Likosky; Jack L Cronenwett
Journal:  Ann Vasc Surg       Date:  2009-09-11       Impact factor: 1.466

View more
  5 in total

1.  Lower Extremity Amputation and Health Care Utilization in the Last Year of Life among Medicare Beneficiaries with ESRD.

Authors:  Catherine R Butler; Margaret L Schwarze; Ronit Katz; Susan M Hailpern; William Kreuter; Yoshio N Hall; Maria E Montez Rath; Ann M O'Hare
Journal:  J Am Soc Nephrol       Date:  2019-02-19       Impact factor: 10.121

2.  Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.

Authors:  Yukihisa Ogawa; Hiroyoshi Yokoi; Takao Ohki; Kimihiko Kichikawa; Masato Nakamura; Kimihiro Komori; Shinsuke Nanto; Erin E O'Leary; Aaron E Lottes; Alan T Saunders; Michael D Dake
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-09       Impact factor: 2.740

3.  Intradialytic hypotension is an important risk factor for critical limb ischemia in patients on hemodialysis.

Authors:  Ryo Matsuura; Sumi Hidaka; Takayasu Ohtake; Yasuhiro Mochida; Kunihiro Ishioka; Kyoko Maesato; Machiko Oka; Hidekazu Moriya; Shuzo Kobayashi
Journal:  BMC Nephrol       Date:  2019-12-19       Impact factor: 2.388

Review 4.  Outcomes of Lower Extremity Endovascular Revascularization: Potential Predictors and Prevention Strategies.

Authors:  Federico Biscetti; Elisabetta Nardella; Maria Margherita Rando; Andrea Leonardo Cecchini; Antonio Gasbarrini; Massimo Massetti; Andrea Flex
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

5.  Bypass surgery versus endovascular intervention for lower extremity revascularization in patients with chronic renal disease or end-stage renal disease: a systematic review and meta-analysis.

Authors:  Yan Sun; Xiaojing Zhou; Jinmei Zhang
Journal:  Int Urol Nephrol       Date:  2021-07-07       Impact factor: 2.370

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.